NFKB1 and neoplasm: Intriguingly, although no activating mutations of NF-κB in CRC have been reported [31], constitutive activation of NF-κB has not only been observed [32,33,34,35] but also been shown to be associated with higher tumor stage [33,36], treatment resistance [32,37,38], and poor survival outcomes [39].